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A B S T R A C T 
Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative malignancy with 
an estimated incidence in the world of 1-2 cases per 100,000 adults. The use of 
Tyrosine Kinase Inhibitors (TKI) as a therapy for CML is still the first choice for 
treatment, but some cases show a high level of resistance or intolerance to TKI 
therapy. This study aims to identify the therapeutic responses of imatinib and nilotinib 
among CML patients in Bandung. 
Method: This study is an analytical descriptive study of CML patients at Hasan Sadikin 
Hospital’s Hematology and Medical Oncology Outpatient Clinic in 2017. The total 
number of samples in this study is 244 patients, consisting of 199 patients with Imatinib 
therapy and 45 patients with Nilotinib therapy. The data is processed using SPSS 
Statistics 22.0 software. 
Result: The results showed that CML patients had a median age of 42 years, sex ratio of 
1: 1 and the highest prevalence was in Bandung City (21.3%). Hematologic response is 
dominated by complete hematologic response, as high as 72.86% with Imatinib and 
66.67% with Nilotinib. Molecular response 3-6 months post therapy is dominated by 
suboptimal response in as many as 36,8% with Imatinib and failure in as many as 50% 
with Nilotinib. Molecular response 12-18 months post therapy is dominated by failure 
in as high as 69,4% with Imatinib and 52,4% with Nilotinib.  
Conclusion: Based on the molecular response, the rates of suboptimal response and 
resistance are quite high. Regular monitoring standards of therapy for CML patients are 
needed to identify TKI resistance so alternative therapies can be provided to improve 
the outcomes. 
  
 
 
INTRODUCTION 
 
Chronic Myeloid Leukemia (CML) is a 
myeloproliferative neoplasm with a worldwide 
incidence of 1 – 2 cases per 100.000 adults. Around 15% 
of CML cases are diagnosed in adulthood. In 2015, 7.000 
new cases of CML were diagnosed in USA causing 
around 1.100 deaths (1). Chronic Myeloid Leukemia is 
caused by the translocation between BCR gene in 
chromosome 22 and ABL gene in chromosome 9. This 
reciprocal translocation forms Philadelphia 
chromosome (t 9;22) which produces the unique BCR-
ABL protein. The protein that is formed relates to the 
kinase activity causing uncontrolled hematopoietic stem 
cells proliferation (2,3). The management of CML 
significantly changed with the development of Tyrosine 
Kinase Inhibitors (TKI) molecules that have the potential 
to intervene the interaction between oncoprotein BCR-
ABL and Adenosine Triphosphate (ATP), leading to 
inhibition of neoplastic cellular proliferation (4). 
The use of TKI as the main therapy for CML is caused 
by its high effectivity. However, nowadays, a few cases 
of CML showed resistance to TKI therapy, up to 1 per 3 
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new cases (1). TKI resistance is defined by the inability 
of TKI drug to achieve pharmacological target, caused by 
the drug itself or by other factors acting as obstacles to 
achieve the treatment target (4). Resistance to TKI can 
be evaluated by hematologic response, cytogenetic 
response, and molecular response after a certain 
amount of time (5,6) 
From a multicentre study in Indonesia, the rate of 
resistance to TKI is higher (47.69%) than in Europe 
(around 24%) (7,8). Until now in Indonesia, specifically 
in West Java there has not been any study describing 
resistance to TKI, in patients using first-line drug 
(imatinib) and  patients using second-line drug 
(nilotinib). Based on the description above, this study 
will review the TKI (imatinib and nilotinib)-resistant 
Chronic Myeloid Leukemia patients in Hasan Sadikin 
Hospital Bandung. 
 
METHODS 
 
This study is an analytical descriptive study with the 
target population of CML patients in Hasan Sadikin 
Hospital. The subjects of this study were CML patients 
at Hasan Sadikin Hospital’s Hematology and Medical 
Oncology Outpatient Clinic in 2017, taken as secondary 
data from patients’ medical records with the inclusion 
criteria of BCR-ABL examination done in 2015-2017 and 
those with complete medical records data. 
The characteristics reviewed including age, sex, 
domicile, TKI being used, BCR-ABL value when first 
diagnosed, hematologic response from TKI, and 
molecular response from TKI. Hematologic response 
was assessed with routine blood check for 3 months 
after TKI therapy. Complete hematologic response is 
indicated by normal leucocytes and thrombocytes 
counts, intolerance is indicated by leucocyte count of 
<4x109/L and/or thrombocyte count of <150x109/L, and 
failure response is indicated by leucocytosis and 
thrombocytosis (6,9).  
Molecular response was assessed by BCR-ABL 
examination with Polymerase Chain Reaction (PCR) 
method. Patients with BCR-ABL value in 3-6 months 
after TKI therapy were then categorized into three 
categories: early molecular response (EMR) (BCR-ABL ≤ 
10%), suboptimal (with decreasing BCR-ABL value), and 
failure in achieving EMR (neither decreasing nor 
increasing BCR-ABL value). Patients with BCR-ABL value 
in 12-18 months after TKI therapy were then 
categorized into three categories: complete molecular 
response (BCR-ABL not detected), major molecular 
response (BCR-ABL value < 0.1% or decrement of ≥ 3 
log), and failure (neither decreasing nor increasing BCR-
ABL value) (6,9). Data was processed using SPSS Statistic 
22.0 software. For numerical data, p value was tested by 
One Way ANOVA test if the data was normally 
distributed and Kruskal-Wallis test if the data was not 
normally distributed. Categorical data p value was 
calculated based on the Chi-Square test with an 
alternative of Kolmogorov-Smirnov and Exact test. Value 
of significance based on p value <0.05 (10,11). 
 
RESULTS 
 
During the study period, there were 301 CML patients 
at Hasan Sadikin Hospital’s Hematology and Medical 
Oncology Outpatient Clinic in 2017, but only 244 of 
these patients fulfilled the criteria for this study.  
The ratio of women to men was 1:1. The median age 
of CML patients was 42 years. Most of these CML 
patients lived in Bandung City (21.3%). As many as 199 
patients used Imatinib and 45 patients used Nilotinib. 
The mean of BCR-ABL value on the first diagnosis was 
28.40±40.733% (Table 1). 
 
Table 1. CML patients characteristics (N = 244) 
 
Characteristics Value 
Age (years)   
 Mean ± SD 41.5±13.5 
 Median 42.00 
 Range (min-max) 15.0-79.0 
Sex 
 
 
Male 122 (50%) 
Female 122 (50%) 
Domicile: N (%) 
 
 
Bandung City 52 (21.3%) 
 
Bandung Regency 40 (16.4%) 
 
Sumedang Regency 17 (7%) 
Subang Regency 13 (5.3%) 
 Sukabumi Regency 12 (4.9%) 
 
Bandung Barat Regency 11 (4.5%) 
Garut Regency 11 (4.5%) 
 Cimahi City 11 (4.5%) 
 Tasikmalaya Regency 10 (4.1%) 
 Majalengka Regency 9 (3.7%) 
 Ciamis Regency 8 (3.3%) 
 Indramayu Regency 8 (3.3%) 
 Karawang Regency 7 (2.9%) 
 Cianjur Regency 6 (2.5%) 
 Purwakarta Regency 6 (2.5%) 
 Cirebon City/ Regency 5 (2.0%) 
 Tasikmalaya City 4 (1.6%) 
 Bekasi Regency 3 (1.2%) 
 Other Cities/ Regencies 11 (4.5%) 
Therapy given: N (%)  
 Imatinib 199 (81.6%) 
 Nilotinib 45 (18.4%) 
BCR-ABL value (First time diagnosed): %  
 Mean±SD 28.4±40.7 
 Median 13.64 
 Range (min-max) 0.0-259.2 
 
 90 Therapeutic response of imatinib and nilotinib among CML patients in Hasan Sadikin Hospital Bandung. 
 
 
 
www.indonesianjournalofcancer.or.id 
In the Imatinib group, average age was 41.12 ± 
13.694, with 49.7% male patients and 50.3% female 
patients. In the Nilotinib group, average age was 43.26 ± 
12.897, with 51.1% male patients and 48.9% female 
patients. TKI therapy showed good hematologic 
response, characterized by the amount of complete 
hematologic response in as many as 72.9% with 
Imatinib, and 66.7% with Nilotinib. While failure to 
achieve hematologic response was seen in 23.3% with 
Imatinib, and 33.3% with Nilotinib (Table 2). 
Molecular responses were assessed in 3-6 months 
post therapy (38 patients with Imatinib and 8 patients 
with Nilotinib) and 12-18 months post therapy (72 
patients with Imatinib and 21 patients with Nilotinib). As 
many as 89 patients with Imatinib and 16 patients with 
Nilotinib were excluded because the BCR-ABL 
examination in Hasan Sadikin Hospital has not been 
carried out in accordance with the standard 
examination after the TKI therapy (Figure 1). 
 
Table 2. Comparison of Age, Gender, Hematological Response and BCR ABL of Patients Given Therapy with Imatinib and Nilotinib 
Variable 
Groups 
P Value Imatinib Nilotinib 
N=199 N=45 
Age (years)   0.338 
Mean±SD 41.1±13.6 43.2±12.8  
Median 41.0 46.0  
Range (min-max) 
 
15.0-79.0 22.0-67.0  
Sex   0.869 
Men 99(49.7%) 23(51.1%)  
Women 
 
100(50.3%) 22(48.9%)  
Hematologic Response   0.208 
Complete  145(72.9%) 30(66.7%)  
Intolerance 7(3.5%) 0(0.0%)  
Failure 47(23.6%) 15(33.3%)  
 
BCR ABL 
   
0.242 
Mean±SD 22.7±37.6 31.3±52.8  
Median 14.8 3.6  
Range (min-max) 00.0-198.3 0.0-259.2  
 
  
Figure 1. Diagram flow of CML patients based on molecular response 
Exclusion = 57 
Data not complete 
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Failure to achieve molecular response due to 
resistance to Imatinib occurred in as many as 29% 
patients in 3-6 months. In these patients, the average 
age was 42.27 ± 12.977, mostly were men (72.7%), and 
there were statistically significant differences in the 
percentage of hematologic responses (p = 0.046) for the 
early molecular response, suboptimal and failed groups 
that were given Imatinib therapy for 3-6 months (Table 
3). 
Failure to achieve molecular response due to 
resistance to Imatinib occurred in as many as 69.4% 
patients in 12-18 months. The average age of these 
patients was 40.72 ± 12,530, and mostly were women 
(54%) (Table 4). 
 
Table 3. Comparison of age, gender, hematologic responses and BCR ABL in the early molecular response, suboptimal and failed groups 
of patients given Imatinib for 3-6 months. 
 
Variable 
Group  
P Value 
Early Molecular 
Response 
Suboptimal Failure 
N=13 (34.2%) N=14 (36.8%) N=11 (29%) 
     
Age (years)    0.341 
Mean ± SD 40.3±20.0 33.8±10.5 42.2±12.9  
Median 36.0 33.0 46.0  
Range (min-max) 17.0-79.0 17.0-56.0 21.0-60.0  
     
Sex    0.487 
Men 7(53.8%) 7(50.0%) 8(72.7%)  
Women 6(46.2%) 7(50.0%) 3(27.3%)  
     
Hematologic Response    0.046** 
Complete  12(92.3%) 6(42.9%) 8(72.7%)  
Intolerance 1(7.7%) 1(7.1%) 0(0.0%)  
Failure 0(0.0%) 7 (50.0%) 3(27.3%)  
 
Table 4. Comparison of age, gender, hematologic response and BCR ABL in the complete molecular response group, major molecular 
response and failed patients given Imatinib for 12-18 months 
 
Variable 
Group 
P Value 
Complete Molecular 
Response 
Major Molecular 
Response 
Failure 
N=12 (16.7%) N=10 (13.9%) N=50 (69.4%) 
     
Age (years)    0.176 
Mean ± SD 36.0±11.6 46.8±18.7 40.7±12.5  
Median 37.0 51.0 40.5  
Range (min-max) 18.0-57.0 16.0-70.0 17.0-69.0  
     
Sex    0.333 
Men 7(58.3%) 7(70.0%) 23(46.0%)  
Women 5(41.7%) 3(30.0%) 27(54.0%)  
     
Hematologic Response    0.152 
Complete  12(100.0%) 9(90.0%) 34(68.0%)  
Intolerance 0(0.0%) 0(0.0%) 1(2.0%)  
Failure 0(0.0%) 1(10.0%) 15(30.0%)  
 
Failure to achieve molecular response due to 
resistance to Nilotinib was observed in as many as 50% 
patients in 3-6 months, with the average age was 40.75 
± 9.105, and most of them were men (75%) (Table 5). 
Failure to achieve molecular response due to resistance 
to Nilotinib was observed in as many as 52.4% patients 
in 12-18 months, with the average age was 43.72 ± 
12,634, and predominantly men (54.5%) (Table 6). 
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Table 5. Comparison of age, gender, hematologic response and BCR ABL in the early molecular response, suboptimal and failed group 
of patients given Nilotinib for 3-6 months. 
 
Variable 
Group  
P Value 
Early Molecular 
Response 
Suboptimal Failure 
N=2 (25%) N=2 (25%) N=4 (50%) 
     
Age (years)    0.410 
Mean ± SD 48.0±15.5 33.5±0.7 40.7±9.1  
Median 48.0 33.5 41.5  
Range (min-max) 37.0-59.0 33.0-34.0 31.0-49.0  
     
Sex    0.513 
Men 1(50.0%) 2(100.0%) 3(75.0%)  
Women 1(50.0%) 0(0.0%) 1(25.0%)  
     
Hematologic Response    0.223 
Complete  1(50.0%) 2(100.0%) 1(25.0%)  
Intolerance 0(0.0%) 0(0.0%) 0(0.0%)  
Failure 1(50.0%) 0(0.0%) 3(75.0%)  
 
 
Table 6. Comparison of age, gender, hematologic response and BCR ABL in the complete molecular response group, major molecular 
response and failed groups in patients given Nilotinib for 12-18 months. 
 
Variable 
Group 
P Value 
Complete Molecular 
Response 
Major Molecular 
Response 
Failure 
N=6 (28.6%) N=4 (19%) N=11 (52.4%) 
     
Age (years)    0.059 
Mean ± SD 54.5±6.4 35.7±20.5 43.7±12.6  
Median 53.0 27.5 45.0  
Range (min-max) 48.0-67.0 22.0-66.0 22.0-64.0  
     
Sex    0.305 
Men 1(16.7%) 2(50.0%) 6(54.5%)  
Women 5(83.3%) 2(50.0%) 5(45.5%)  
     
Hematologic Response    0.169 
Complete  5(83.3%) 4(100.0%) 6(54.5%)  
Intolerance 0(0.0%) 0(0.0%) 0(0.0%)  
Failure 1(16.7%) 0(0.0%) 5(45.5%)  
 
 
 
DISCUSSION 
 
In this study we obtained samples as many as 244 
patients. Within CML patients around the world, 
including Asia and Indonesia, the cases occur more 
often in male than female (8). But the result of our 
study showed equal percentages in male and female 
patients. The median of age for CML cases in the world 
is 65 years old, while in Indonesia the median of age for 
CML cases is 36 years old, similar to the median of age 
for CML cases in Asia (8). But in this study we found that 
the median of age was 42 years old.  
Based on the domicile in West Java, five areas with 
most CML patients visiting the Outpatient Department 
of Hematology and Medical Oncology in Hasan Sadikin 
Hospital in 2017 were Bandung City with 52 patients 
(21.3%), Bandung Regency with 40 patients (16.4%), 
Sumedang Regency with 17 patients (7%), Subang 
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Regency with 13 patients (5.3%) and Sukabumi Regency 
with 12 patients (4.9%). Based on the therapy given, 199 
patients (81.6%) were given Imatinib, and 45 patients 
(18.4%) were given Nilotinib. Based on BCR-ABL value in 
the first examination, we found a median value of 
25.77%, a mean of 40.83%, a minimum value of 0% 
(negative) and a maximum value of 286.07%.  
American Cancer Society classifies treatment 
response in Chronic Myeloid Leukemia as hematologic 
response, cytogenetic response, and molecular 
response. Hematologic response is assessed from 
complete blood count in the first 3 months of 
treatment, cytogenetic response is assessed from bone 
marrow examination, and molecular response is 
assessed by PCR testing of BCR-ABL gene in 3-6 month 
and 12-18 month of therapy (6) European Leukemia also 
classifies suboptimal and failed molecular response 
criteria based on post-therapy time evaluation. (Table 
7). In this study, the treatment responses were only 
evaluated by hematologic and molecular responses to 
Imatinib and Nilotinib. 
 
Table 7. Criteria for suboptimal and failure responses according to European LeukemiaNet. 
 
Evaluation Time (Month) Suboptimal Response Failure 
0 - - 
3 No CyR (Ph+ >95%) Less than CHR 
6 Less than PCyR (Ph+ >35%) No CyR (Ph+ >95%) 
12 PCyR (Ph+ 1% – 35%) Less than PCyR (Ph+ >35%) 
18 Less than MMR Less than CCyR 
Any Time The loss of MMR, mutation of BCR-ABL The loss of CHR, the loss of CCyR, mutation of 
BCR-ABL, CCA/Ph+ 
 
CHR = complete hematologic response (Thrombocyte < 450x109/L; Leucocyte < 10x109/L; differential count without immature 
granulocytes), CyR = cytogenic response, PCyR = Partial complete cytogenic response, CCyR = Complete cytogenetic response, MMR = 
Major molecular response (BCR-ABL <0,1, CCA/Ph+= clonal evolution 
The patients in this study showed high rate of 
complete hematologic response from TKI. Treatment 
response to Imatinib showed that as many as 145 
patients (72.86%) experienced complete hematologic 
response, 7 patients (3.52%) experienced intolerance 
and 47 patients (23.52%) experienced failure. While 
treatment response to nilotinib as second-line drug 
showed that as many as 30 patients (66.67%) 
experienced complete hematologic response and as 
many as 15 patients (33.3%) experienced failure. 
Based on the 3-6 months molecular response and 12-
18 months post Imatinib and Nilotinib therapy, there 
were 89 data on Imatinib therapy and 16 data on 
Nilotinib therapy that cannot be assessed because the 
BCR-ABL examination in Hasan Sadikin Hospital was not 
routinely done in every patient (Figure 1).  
Molecular responses based on BCR-ABL data in 3-6 
months after imatinib therapy found that 13 patients 
(34.2%) experienced an early molecular response, 14 
patients (36.8%) experienced suboptimal and 11 
patients (29%) experienced resistance or failure. In the 
failure group, the average age of patients was 42.27 ± 
12.977, with the highest percentage occurring in men 
(72.7%) compared to women. There was no statistically 
significant difference in age (p = 0.341) and sex (p = 
0.487) for the early molecular response, suboptimal and 
failed groups. However, there were statistically 
significant differences in hematologic responses (p = 
0.046) for the early molecular response, suboptimal and 
failed groups. This means that the hematologic response 
is directly proportional to the early molecular response 
in 3-6 months evaluation of TKI in CML patient. Failure 
to achieve a hematologic response also means failure to 
achieve an early molecular response. This is similar to 
previous studies that stated complete hematologic 
response must be achieved within 3 months of therapy 
(6).  
Based on BCR-ABL data in 12-18 months after 
Imatinib therapy, 12 patients (16.7%) experienced 
complete molecular response, 10 patients (13.9%) 
experienced major molecular response, and 50 patients 
(69,4%) experienced failure. In the failure group, the 
average age of patients was 40.72 ± 12.530, with the 
highest percentage occurring in women (54.0%) 
compared to men. There was no statistically significant 
differences in age (p = 0.176), sex (p = 0.333) and 
hematologic response (p = 0.152) for the complete 
molecular response group, major molecular response 
and failure groups. 
Molecular response based on BCR-ABL data in 3-6 
months after Nilotinib therapy found that 2 patients 
(25%) experienced an early molecular response, 2 
patients (25%) experienced a suboptimal response and 
4 patients (50%) experienced failure. In the failure 
group, the average age of patients was 40.75 ± 9.105, 
with the highest percentage occurring in men (75.0%) 
compared to women. There were no statistically 
significant differences in age (p = 0.410), sex (p = 0.513) 
and hematologic response (p = 0.223) for the early 
molecular response, suboptimal and failure groups. 
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Based on BCR-ABL data in 12-18 months after 
nilotinib therapy, 6 patients (28.6%) experienced 
complete molecular response, 4 patients (19%) 
experienced major molecular response, and 11 patients 
(52.4%) experienced failure. In the failure group, the 
average age of patients was 43.72 ± 12.634, with the 
highest percentage occurring in men (54.5%) compared 
to women. There were no statistically significant 
differences in age (p = 0.059), sex (p = 0.305) and 
hematologic response (p = 0.169) for the complete 
molecular response group, major molecular response 
and failure groups.  
 This study shows that Imatinib and Nilotinib have 
good response toward patients’ hematologic status. 
Based on molecular response in 12-18 months after 
therapy, resistance rate in Imatinib is higher than 
Nilotinib. This is similar to previous studies that stated 
Imatinib as a first-line standard treatment choice with 
increasing resistance frequency (3). 
One of the articles explaining that in the last few 
years, resistance to Tyrosine Kinase Inhibitor has 
become a distinctive challenge in the management of 
Chronic Myeloid Leukemia. Knowledge is needed in 
identifying all of the resistance mechanisms in CML 
therapy, to optimize the use of various TKI and 
combination of TKI as a new drug that can specifically 
prevent leukemic stem cell transformation and 
eradicate CML disease (12,13). 
 
CONCLUSION 
Even though TKI therapy gives effective response 
based on the hematologic response, it still shows a quite 
high rate of suboptimal and resistance rate based on the 
molecular response. Regular monitoring standards of 
therapy for CML patients are needed to identify TKI 
resistance so that alternative therapies can be provided 
and improve outcomes. 
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